HC Wainwright Forecasts BioAtla’s Q2 Earnings (NASDAQ:BCAB)

BioAtla, Inc. (NASDAQ:BCAB) – Research analysts at HC Wainwright cut their Q2 2025 earnings estimates for BioAtla in a note issued to investors on Wednesday, May 7th. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.29) for the quarter, down from their previous estimate of ($0.28). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for BioAtla’s Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.84) EPS and FY2029 earnings at ($0.91) EPS.

BioAtla Stock Performance

Shares of BioAtla stock opened at $0.44 on Monday. The stock has a 50 day moving average price of $0.37 and a 200-day moving average price of $0.78. The stock has a market cap of $25.67 million, a price-to-earnings ratio of -0.26 and a beta of 1.01. BioAtla has a one year low of $0.24 and a one year high of $3.32.

BioAtla (NASDAQ:BCAB) last announced its earnings results on Tuesday, May 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.01).

Institutional Trading of BioAtla

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Anson Funds Management LP purchased a new stake in BioAtla in the fourth quarter worth $2,720,000. Acorn Capital Advisors LLC purchased a new stake in shares of BioAtla in the 4th quarter worth approximately $2,384,000. Highbridge Capital Management LLC bought a new stake in BioAtla during the 4th quarter valued at $1,484,000. Tang Capital Management LLC boosted its position in BioAtla by 57.2% during the fourth quarter. Tang Capital Management LLC now owns 1,374,076 shares of the company’s stock valued at $812,000 after purchasing an additional 500,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of BioAtla by 62.2% in the 4th quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock worth $490,000 after buying an additional 318,196 shares during the last quarter. 77.23% of the stock is owned by hedge funds and other institutional investors.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.